Global Influenza Vaccine Market 2018-2022
SKU ID : TNV-11638540 | Publishing Date : 09-Jan-2018 | No. of pages : 113
Detailed TOC of Global Influenza Vaccine Market 2018-2022
Table of ContentsPART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
• Overview
• Comparison by vaccine type
• Global live attenuated influenza vaccines market
• Global recombinant influenza vaccines market
• Market opportunity by vaccine type
PART 10: MARKET SEGMENTATION BY AGE GROUP
• Adults
• Pediatrics
PART 11: CUSTOMER LANDSCAPE
PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Influenza vaccine market in Americas
• Influenza vaccine market in EMEA
• Influenza vaccine market in APAC
• Market opportunity
PART 13: DECISION FRAMEWORK
PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 15: MARKET TRENDS
• Strong pipeline
• Strategic alliances
PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 17: VENDOR ANALYSIS
• Overview
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• CSL
• GlaxoSmithKline
• Sanofi
PART 18: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global vaccine market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global influenza vaccine market 2017-2022 ($ millions)
Exhibit 09: Global influenza vaccine market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials candidates of influenza vaccines
Exhibit 20: Global influenza vaccine market by vaccine type 2017-2022 (%)
Exhibit 21: Comparison by vaccine type
Exhibit 22: Global live attenuated influenza vaccines market 2017-2022 ($ millions)
Exhibit 23: Global live attenuated influenza vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 24: Global recombinant influenza vaccines market 2017-2022 ($ millions)
Exhibit 25: Global recombinant influenza vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by vaccine type
Exhibit 27: Adult influenza vaccine products and their cost
Exhibit 28: Pediatric influenza vaccine products and their cost
Exhibit 29: Customer landscape
Exhibit 30: Global influenza vaccine market by geography 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Influenza vaccine market in Americas 2017-2022 ($ millions)
Exhibit 33: Influenza vaccine market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: Influenza vaccine market in EMEA 2017-2022 ($ millions)
Exhibit 36: Influenza vaccine market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: Influenza vaccine market in APAC 2017-2022 ($ millions)
Exhibit 39: Influenza vaccine market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Market opportunity
Exhibit 42: Distribution of influenza vaccine doses in US by season
Exhibit 43: Steps for production of IIV
Exhibit 44: Molecules in phase III with sponsors
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendor landscape
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca: Overview
Exhibit 51: AstraZeneca: Business segments
Exhibit 52: AstraZeneca: Organizational developments
Exhibit 53: AstraZeneca: Geographic focus
Exhibit 54: AstraZeneca: Segment focus
Exhibit 55: AstraZeneca: Key offerings
Exhibit 56: AstraZeneca: Key customers
Exhibit 57: CSL: Overview
Exhibit 58: CSL: Business segments
Exhibit 59: CSL: Organizational developments
Exhibit 60: CSL: Geographic focus
Exhibit 61: CSL: Segment focus
Exhibit 62: CSL: Key offerings
Exhibit 63: CSL: Key customers
Exhibit 64: GlaxoSmithKline: Overview
Exhibit 65: GlaxoSmithKline: Business segments
Exhibit 66: GlaxoSmithKline: Organizational developments
Exhibit 67: GlaxoSmithKline: Geographic focus
Exhibit 68: GlaxoSmithKline: Segment focus
Exhibit 69: GlaxoSmithKline: Key offerings
Exhibit 70: GlaxoSmithKline: Key customers
Exhibit 71: Sanofi: Overview
Exhibit 72: Sanofi: Business segments
Exhibit 73: Sanofi: Organizational developments
Exhibit 74: Sanofi: Geographic focus
Exhibit 75: Sanofi: Segment focus
Exhibit 76: Sanofi: Key offerings
Exhibit 77: Sanofi: Key customers